Cabaletta Bio Inc

NASDAQ:CABA   4:00:00 PM EDT
1.52
-0.05 (-3.18%)
: $1.55 +0.03 (+1.97%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)136.72M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$4.17 Million
Adjusted EPS-$0.65
See more estimates
10-Day MA$1.69
50-Day MA$1.67
200-Day MA$2.55
See more pivots

Cabaletta Bio Inc Stock, NASDAQ:CABA

2929 Arch Street, Suite 600, Philadelphia, Pennsylvania 19104
United States of America
Phone: +1.267.759.3100
Number of Employees: 103

Description

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.